表紙
市場調查報告書

市場聚光燈:結核 (TB)

Market Spotlight: Tuberculosis (TB)

出版商 Datamonitor Healthcare 商品編碼 914887
出版日期 內容資訊 英文 43 Pages
商品交期: 最快1-2個工作天內
價格
市場聚光燈:結核 (TB) Market Spotlight: Tuberculosis (TB)
出版日期: 2020年08月21日內容資訊: 英文 43 Pages
簡介

本報告提供全球結核 (TB) 治療藥市場相關調查分析,主要的上市藥、開發平台藥物,臨床實驗,最近的活動、分析師的見解,未來、規定活動,成功的概率,專利資訊,10年預測,許可證、收購交易相關的系統性資訊。

概要

要點

疾病的背景

  • 疾病定義
  • 患者的亞型
  • 症狀
  • 風險因素
  • 診斷

治療

  • 抗結核藥
  • 手術

流行病學

上市藥

開發平台藥物

最近的活動和分析師的見解

今後的活動

主要的法規活動

成功的概率

許可證、資產取得交易

本源專利

臨床實驗形勢

  • 贊助商:各狀況
  • 贊助商:各階段

參考文獻

附錄

目錄
Product Code: DMKC0204837

This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.

Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being topical and intravenous formulations.

The majority of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in mid-to-late-stage development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being tested in intramuscular and intradermal formulations.

The only high-impact upcoming event for drugs in the TB space is topline Phase II trial results for GSK3036656. The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 24.6%, and the average probability a drug advances from Phase III is 62.9%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.1 years in the overall infectious disease space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TB have been in the early and midphases of development, with 74% of trials in Phase I-II, and only 26% in Phase III-IV.

South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.

GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Anti-TB drugs
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Pretomanid for TB (June 6, 2019)
  • Pretomanid for TB (June 4, 2019)
  • Pretomanid for TB (April 18, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Pediatric Approvals In TB, Bladder Dysfunction, And Atopic Dermatitis
  • Mylan Gets Expert Panel Go-Ahead For Pretomanid In India
  • Global Approvals Snapshot: November 2019
  • Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Pfizer Deal Covers Sutezolid For TB
  • Deals Shaping The Medical Industry, December 2019
  • Shionogi, Hsiri Expand Mycobacterial R&D Pact
  • BioNTech Gets Gates Foundation Funding For HIV, TB Drug Discovery

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Global trends in incident cases of tuberculosis, 2018-27
  • Figure 2: Overview of pipeline drugs for tuberculosis in the US
  • Figure 3: Pipeline drugs for tuberculosis, by company
  • Figure 4: Pipeline drugs for tuberculosis, by drug type
  • Figure 5: Pipeline drugs for tuberculosis, by classification
  • Figure 6: Key upcoming events in tuberculosis
  • Figure 7: Probability of success in the tuberculosis pipeline
  • Figure 8: Clinical trials in tuberculosis
  • Figure 9: Top 10 drugs for clinical trials in tuberculosis
  • Figure 10: Top 10 companies for clinical trials in tuberculosis
  • Figure 11: Trial locations in tuberculosis
  • Figure 12: Tuberculosis trials status
  • Figure 13: Tuberculosis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Global incident cases of tuberculosis, 2018-27
  • Table 2: Global incident cases of tuberculosis with HIV, 2018
  • Table 3: Global incident cases of MDR/RR tuberculosis, 2018
  • Table 4: Marketed drugs for tuberculosis
  • Table 5: Pipeline drugs for tuberculosis in the US
  • Table 6: Pretomanid for TB (June 6, 2019)
  • Table 7: Pretomanid for TB (June 4, 2019)
  • Table 8: Pretomanid for TB (April 18, 2019)